IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

David H. Persing et al.

Application No.

09/991,376

Filed

November 20, 2001

For

PROPHYLACTIC AND THERAPEUTIC TREATMENT OF

INFECTIOUS AND OTHER DISEASES WITH MONO- AND

DISACCHARIDE-BASED COMPOUNDS

Docket No.

: 210121.530C1

Commissioner for Patents Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO-1449 (copies of the cited references are enclosed). As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,
Seed Intellectual Property Law Group PLLC

Jeffrey Hundley, Ph.D. Registration No. 42,676

JEH:mls

701 Fifth Avenue, Suite 6300 Seattle, Washington 98104-7092

Phone: (206) 622-4900 Fax: (206) 682-6031 FORM PTO-1449 ATTY. DOCKET NO. APPLICATION NO. U.S. DEPARTMENT OF COMMERCE (REV.7-80) PATENT AND TRADEMARK OFFICE 210121.530C1 09/991,376 APPLICANTS INFORMATION DISCLOSURE STATEMENT David H. Persing et al. (Use several sheets if necessary) FILING DATE GROUP ART UNIT November 20, 2001 U.S. PATENT DOCUMENTS *EXAMINER FILING DATE DOCUMENT NUMBER DATE CLASS SUBCLASS INITIAL IF APPROPRIATE 435 AA 6,303,347 10/16/01 Johnson et al. 101 6,113,918 09/05/00 Johnson et al. 424 278.1 4,987,237 549 01/22/91 Myers et al. 222 AC 4,912,094 03/27/90 Myers et al. 514 54 AD 4,877,611 10/31/89 Cantrell 424 88 AF 4,866,034 09/12/89 Ribi 514 424 AG | 4,436,727 03/13/84 Ribi 177 **FOREIGN PATENT DOCUMENTS** TRANSLATION DOCUMENT DATE COUNTRY NUMBER YES NO WO 98/50399 11/12/98 WIPO AΗ OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) Johnson et al., "3-O-desacyl monophosphoryl lipid A derivatives: synthesis and ΑI immunostimulant activities," J. Med. Chem. 42:4640-4649, 1999. Kirschning et al., "Human toll-like receptor 2 confers responsiveness to bacterial ΑJ lipopolysaccharide," J. Exp. Med. 188(11):2091-2097, December 7, 1998. Poltorak et al., "Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in ΑK Tlr4 gene," Science 282:2085-2088, December 11, 1998. Qureshi et al., "Endotoxin-tolerant mice have mutations in toll-like receptor 4 (Tlr4)," J. AL. Exp. Med. 189(4):615-625, February 15, 1999. Ulrich and Meyers, in Vaccine Design: The Subunit and Adjuvant Approach: Powell and AM Newman Eds.; Plenum: New York, 495-524, 1995. Yang et al., "Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signaling," AN Nature 395:284-288, September 17, 1998. **EXAMINER** DATE CONSIDERED * EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s)

Attorney Docket No.: 014058-017650US

Client Reference No.: 530C3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

DAVID H. PERSING, ET AL.

Application No.: not known

Filed: not known

For: PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS AND OTHER DISEASES WITH MONO- AND DISACCHARIDE

COMPOUNDS

Examiner: not known

Art Unit: not known

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37

CFR §1.97 and §1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are not enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that <u>no fee is required</u> for submission of this statement.

However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

DAVID H. PERSING, ET AL. Application No.: 10/128,156

Page 2

Respectfully submitted,

Joel G. Ackerman Reg. No. 24,307

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834 Tel: 415-576-0200

Fax: 415-576-0300

JA:ja 60114191 v1

Substitute for form 1449A/PTO				Complete if Known		
		_		Application Number	10/128,156	
INFO	ORMATION	N DIS	CLOSURE	Filing Date	April 22, 2002	
STA	STATEMENT BY APPLICANT			First Named Inventor	Persing, David H.	
				Art Unit	1623	
(use as many sheets as necessary)			necessary)	Examiner Name	KATHLEEN FONDA	
Sheet	1	of		Attorney Docket Number	014058-017640US	

			U.S. PATENT DO	CUMENTS+	
Examiner Initials*	Cite No.1	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,844,894	07-04-1989	Ribi	
	AB	US-5,762,943	06-09-1998	Dolovich et al.	
,	AC	US-6,113,918	09-05-2000	Johnson et al.	
	AD	US-6,303,347	10-16-2001	Johnson et al.	
	AE	US-6,355,257	03-12-2002	Johnson et al.	
	AF	US-2002/0009456	01-04-2002	Crane	
	AG	US-2002/0048588	04-25-2002	Johnson et al	
	AH	US-			
	Al	US-			
	AJ	US-	,		
	· AK	US-			
	; AL	US-			
	AM	US-			
	AN	US-			
	AO	US-			
	AP	US-			
	AQ	US-			
	AR	US-			
	AS	US-		·	
	AT	US-			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
		Country Code ³	Number⁴	Kind Code ⁶ (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶
	AU		•	-				
	AV							
	AW							
	AX	1						
	AY	1						
	AZ					,		
	BA							
	BB							

Examiner Signature	Date Considered	

Substitute	for form 1449B/PT	0	Complete if Known			
INFO	DRA A TION	DISCLOSURE	Application Number	10/128,156		
			Filing Date	April 22, 2002		
SIAI	EMEN! B	Y APPLICANT	First Named Inventor	Persing, David H.		
		·	Art Unit	1623		
(1	ise as many sh	eets as necessary)	Examiner Name	KATHLEEN FONDA		
Sheet	2	of	Attorney Docket Number	014058-017640US		

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2				
•	вс	·					
	BD						
-	BE						
	BF						
	BG						
	вн						
	BI	-					
	BJ						
	вк						
	BL _.						
	ВМ						

Examiner	Date	•••	
Signature	Considered	1	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.